Opus Genetics (IRD) Competitors

$4.44 +0.18 (+4.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.38 -0.06 (-1.35%)

As of 06:50 PM Eastern

IRD vs. IMCR, AMLX, CMPS, KALV, and IMTX

Should you buy Opus Genetics stock or one of its competitors? MarketBeat compares Opus Genetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Opus Genetics include Immunocore (IMCR), Amylyx Pharmaceuticals (AMLX), Compass Pathways (CMPS), KalVista Pharmaceuticals (KALV), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry.

How does Opus Genetics compare to Immunocore?

Opus Genetics (NASDAQ:IRD) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, Opus Genetics had 18 more articles in the media than Immunocore. MarketBeat recorded 19 mentions for Opus Genetics and 1 mentions for Immunocore. Immunocore's average media sentiment score of 0.59 beat Opus Genetics' score of -0.24 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immunocore has a net margin of -6.68% compared to Opus Genetics' net margin of -892.36%. Immunocore's return on equity of -7.07% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Immunocore	-6.68%	-7.07%	-2.55%

Opus Genetics presently has a consensus price target of $10.20, indicating a potential upside of 129.73%. Immunocore has a consensus price target of $57.75, indicating a potential upside of 95.50%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.79
Immunocore	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60

Opus Genetics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Immunocore has higher revenue and earnings than Opus Genetics. Immunocore is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	25.45	-$49.59M	-$1.33	N/A
Immunocore	$400.02M	3.74	-$35.51M	-$0.55	N/A

Summary

Immunocore beats Opus Genetics on 9 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to Amylyx Pharmaceuticals?

Opus Genetics (NASDAQ:IRD) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Opus Genetics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	25.45	-$49.59M	-$1.33	N/A
Amylyx Pharmaceuticals	$87.37M	17.32	-$144.74M	-$1.50	N/A

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Opus Genetics had 16 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 19 mentions for Opus Genetics and 3 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of -0.12 beat Opus Genetics' score of -0.24 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Opus Genetics currently has a consensus price target of $10.20, indicating a potential upside of 129.73%. Amylyx Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 68.99%. Given Opus Genetics' stronger consensus rating and higher probable upside, research analysts clearly believe Opus Genetics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.79
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Opus Genetics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Summary

Opus Genetics beats Amylyx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Compass Pathways has a beta of 2.39, indicating that its share price is 139% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

46.2% of Compass Pathways shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Compass Pathways had 13 more articles in the media than Opus Genetics. MarketBeat recorded 32 mentions for Compass Pathways and 19 mentions for Opus Genetics. Compass Pathways' average media sentiment score of 0.73 beat Opus Genetics' score of -0.24 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	5 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Opus Genetics has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Opus Genetics	$14.20M	25.45	-$49.59M	-$1.33	N/A

Compass Pathways currently has a consensus target price of $20.58, indicating a potential upside of 89.36%. Opus Genetics has a consensus target price of $10.20, indicating a potential upside of 129.73%. Given Opus Genetics' higher probable upside, analysts clearly believe Opus Genetics is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.79

Compass Pathways has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Compass Pathways' return on equity of -31.07% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Opus Genetics	-892.36%	-338.88%	-191.21%

Summary

Compass Pathways beats Opus Genetics on 9 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to KalVista Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

15.0% of Opus Genetics shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

KalVista Pharmaceuticals currently has a consensus target price of $30.60, indicating a potential upside of 14.14%. Opus Genetics has a consensus target price of $10.20, indicating a potential upside of 129.73%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.79

KalVista Pharmaceuticals has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

KalVista Pharmaceuticals has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Opus Genetics' return on equity of -338.88% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Opus Genetics	-892.36%	-338.88%	-191.21%

Opus Genetics has lower revenue, but higher earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$49.08M	29.08	-$109.52M	-$3.46	N/A
Opus Genetics	$14.20M	25.45	-$49.59M	-$1.33	N/A

In the previous week, Opus Genetics had 14 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 19 mentions for Opus Genetics and 5 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of -0.14 beat Opus Genetics' score of -0.24 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
KalVista Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Opus Genetics beats KalVista Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Immatics?

Immatics (NASDAQ:IMTX) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Immatics has a net margin of -572.35% compared to Opus Genetics' net margin of -892.36%. Immatics' return on equity of -47.36% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Opus Genetics	-892.36%	-338.88%	-191.21%

64.4% of Immatics shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Opus Genetics has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	27.55	-$222.26M	-$1.99	N/A
Opus Genetics	$14.20M	25.45	-$49.59M	-$1.33	N/A

In the previous week, Opus Genetics had 17 more articles in the media than Immatics. MarketBeat recorded 19 mentions for Opus Genetics and 2 mentions for Immatics. Immatics' average media sentiment score of 0.00 beat Opus Genetics' score of -0.24 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immatics currently has a consensus target price of $19.00, suggesting a potential upside of 69.34%. Opus Genetics has a consensus target price of $10.20, suggesting a potential upside of 129.73%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.79

Immatics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Summary

Opus Genetics beats Immatics on 9 of the 17 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRD vs. The Competition

Export

Metric	Opus Genetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$346.74M	$3.27B	$6.30B	$12.12B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-3.34	18.42	21.04	25.21
Price / Sales	25.45	272.58	530.14	73.07
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	-7.93	6.81	9.91	6.94
Net Income	-$49.59M	$24.18M	$3.55B	$335.25M
7 Day Performance	-11.73%	-0.25%	-0.30%	-0.70%
1 Month Performance	-19.86%	-4.58%	-2.34%	-0.90%
1 Year Performance	346.68%	55.65%	30.89%	29.67%

Opus Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRD Opus Genetics	3.1524 of 5 stars	$4.44 +4.2%	$10.20 +129.7%	+322.1%	$346.74M	$14.20M	N/A	14	Upcoming Earnings Insider Trade Analyst Revision
IMCR Immunocore	3.217 of 5 stars	$28.93 +2.0%	$57.75 +99.6%	-6.7%	$1.44B	$400.02M	N/A	320
AMLX Amylyx Pharmaceuticals	2.6823 of 5 stars	$12.74 -0.9%	$23.00 +80.5%	+137.7%	$1.43B	$87.37M	N/A	200	Gap Up
CMPS Compass Pathways	3.7928 of 5 stars	$10.07 -4.6%	$20.58 +104.4%	+131.5%	$1.43B	N/A	N/A	120	Trending News Earnings Report Options Volume Analyst Revision
KALV KalVista Pharmaceuticals	2.4549 of 5 stars	$26.76 0.0%	$30.60 +14.4%	+121.7%	$1.42B	$49.08M	N/A	100	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRD) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Opus Genetics (IRD) Competitors

IRD vs. IMCR, AMLX, CMPS, KALV, and IMTX

How does Opus Genetics compare to Immunocore?

Summary

How does Opus Genetics compare to Amylyx Pharmaceuticals?

Summary

How does Opus Genetics compare to Compass Pathways?

Summary

How does Opus Genetics compare to KalVista Pharmaceuticals?

Summary

How does Opus Genetics compare to Immatics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Opus Genetics (IRD) Competitors

IRD vs. IMCR, AMLX, CMPS, KALV, and IMTX

How does Opus Genetics compare to Immunocore?

Does the media prefer IRD or IMCR?

Do insiders & institutionals believe in IRD or IMCR?

Is IRD or IMCR more profitable?

Do analysts prefer IRD or IMCR?

Which has more volatility & risk, IRD or IMCR?

Which has higher valuation and earnings, IRD or IMCR?

Summary

How does Opus Genetics compare to Amylyx Pharmaceuticals?

Which has preferable earnings and valuation, IRD or AMLX?

Do insiders & institutionals have more ownership in IRD or AMLX?

Does the media refer more to IRD or AMLX?

Do analysts recommend IRD or AMLX?

Which has more risk and volatility, IRD or AMLX?

Is IRD or AMLX more profitable?

Summary

How does Opus Genetics compare to Compass Pathways?

Which has more volatility & risk, CMPS or IRD?

Do insiders & institutionals have more ownership in CMPS or IRD?

Does the media prefer CMPS or IRD?

Which has better earnings & valuation, CMPS or IRD?

Do analysts prefer CMPS or IRD?

Is CMPS or IRD more profitable?

Summary

How does Opus Genetics compare to KalVista Pharmaceuticals?

Do institutionals and insiders have more ownership in KALV or IRD?

Do analysts rate KALV or IRD?

Which has more volatility & risk, KALV or IRD?

Is KALV or IRD more profitable?

Which has preferable valuation and earnings, KALV or IRD?

Does the media refer more to KALV or IRD?

Summary

How does Opus Genetics compare to Immatics?

Is IMTX or IRD more profitable?

Do institutionals and insiders hold more shares of IMTX or IRD?

Which has better earnings & valuation, IMTX or IRD?

Does the media prefer IMTX or IRD?

Do analysts rate IMTX or IRD?

Which has more risk & volatility, IMTX or IRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools